CTOs on the Move


 
The Vitals 360® measures 6 key vital signs. It´s like having a portable doctor´s office in the home or anywhere. Heart Rate Blood Pressure Blood Oxygen Saturation ECG Heart Rhythms Temperature Glucose (Not available in the...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.vocare.com
  • 8888, Keystone Crossing
    Indianapolis, IN USA 46240
  • Phone: 317.658.0005

Executives

Name Title Contact Details

Similar Companies

Shire

At Shire, we enable people with life altering conditions to lead better lives. We focus on developing and delivering innovative treatments for patients with rare diseases and other specialty conditions.To realize our aspiration to become a leading global biotech, our efforts are concentrated on four key strategic drivers: growth, innovation, efficiency, and people. Our priorities are to drive optimal performance of our existing products, increase patient access to these medicines, and to build our pipeline through research and development and partnerships in order to deliver new medicines to patients.

Acro Pharmaceutical Services

Acro Pharmaceutical Services is a Sharon Hill, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bayless Integrated Healthcare

Bayless Healthcare offers a progressive approach to Integrated Healthcare in the Phoenix area. Services include primary care, behavioral health & counseling services & wellness programs.

GFS Chemicals

GFS Chemicals is a Powell, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mustang Bio

Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers. Mustang`s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia.